Aripiprazole in the treatment of schizophrenia: Safety and tolerability in short-term, placebo-controlled trials

Schizophrenia Research

Volumn 61, Issue 2-3, 2003, Pages 123-136

  Marder, Stephen R ^a   McQuade, Robert D ^b   Stock, Elyse ^b   Kaplita, Stephen ^b   Marcus, Ronald ^b   Safferman, Allan Z ^b   Saha, Anutosh ^c   Ali, Mirza ^c   Iwamoto, Taro ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^d OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Aripiprazole; Atypical antipsychotics; Dopamine serotonin system stabilizer; Safety; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; CHOLESTEROL; GLUCOSE; HALOPERIDOL; PLACEBO; PROLACTIN;

AGITATION; AKATHISIA; ANALYTIC METHOD; ANXIETY; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ELECTROCARDIOGRAPHY; EXTRAPYRAMIDAL SYNDROME; GLUCOSE BLOOD LEVEL; HEADACHE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INSOMNIA; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; QT INTERVAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RISK ASSESSMENT; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; VERTIGO; VOMITING;

EID: 0037410337     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(03)00050-1     Document Type: Article

References (45)

1. Allison D.B., Casey D.E. Antipsychotic-induced weight gain: a review of the literature. J. Clin. Psychiatry. 62:2001;22-31.
2. Beasley C.M. Jr., Tollefson G., Tran P., Satterlee W., Sanger T., Hamilton S. Olanzapine versus placebo and haloperidol. Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 14:1996;111-123.
3. Beasley C.M. Jr., Tollefson G.D., Tran P.V. Safety of olanzapine. J. Clin. Psychiatry. 58(Suppl. 10):1997;13-17.
4. Brown S., Birtwistle J., Roe L., Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol. Med. 29:1999;697-701.
5. Burris K.D., Molski T.F., Xu C., Ryan E., Tottori K., Kikuchi T., Yocca F.D., Molinoff P.B. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human D2 dopamine receptors. J. Pharmacol. Exp. Ther. 302:2002;381-389.
6. Carlsson A., Waters N., Waters S., Carlsson M.L. Network interactions in schizophrenia - therapeutic implications. Brain Res. Rev. 31:2000;342-349.
7. Carson W.H., McQuade R.D., Ali M., Saha A.R., Dunbar G.C., Ingenito G. A double-blind, placebo-controlled trial of aripiprazole and haloperidol. Schizophr. Res. 49(Suppl. 1):2001;221.
8. Carson W.H., Pigott T.A., Saha A.R., Ali M.W., McQuade R.D., Torbeyns A.F., Stock E.G. Aripiprazole vs. placebo in the treatment of chronic schizophrenia. Int. J. Neuropsychopharmacol. 5(Suppl. 1):2002;S187.
9. Casey D.E. Motor and mental aspects of acute extrapyramidal syndromes. Acta Psychiatr. Scand. 380:1994;14-20.
10. Cornblatt B., Kern R.S., Carson W.H., Stock E., Ali M., Ingenito G., Green M.F. Neurocognitive effects of aripiprazole versus olanzapine in patients with stable psychosis. Schizophr. Res. 53(3 Suppl.):2002;1-274.
11. Davies A., Adena M.A., Keks N.A., Catts S.V., Lambert T., Schweitzer I. Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety. Clin. Ther. 20:1998;58-71.
12. Dickson R.A., Glazer W.M. Neuroleptic-induced hyperprolactinemia. Schizophr. Res. 35:1999;S75-S86.
13. Fleischhacker W.W., Meise U., Gunther V., Kurz M. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr. Scand., Suppl. 382:1994;11-15.
14. Gaebel W. Towards the improvement of compliance: the significance of psycho-education and new antipsychotic drugs. Int. Clin. Psychopharmacol. 12(Suppl. 1):1997;S37-S42.
15. Glassman A.H., Bigger J.T. Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am. J. Psychiatry, Nov. 158(11):2001;1774-1782.
16. Glennon R.A., Dukat M. Serotonin subtypes and their characteristics. Bloom F.E., Kupfer D.J. Psychopharmacology: The Fourth Generation of Progress. 1995;415-429 Raven Press, New York.
17. Gury C., Canceil O., Iaria P. Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia. Encephale. 26(6):2000;62-72.
18. Hennessy S., Bilker W.B., Knauss J.S., Margolis D.J., Kimmel S.E., Reynolds R.F., Glasser D.B., Morrison M.F., Strom B.L. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ, Nov. 9. 325(7372):2002;1070.
19. Inoue T., Domae M., Yamada K., Furukawa T. Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)- quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J. Pharmacol. Exp. Ther. 277:1996;137-143.
20. Ishigooka J., Murasaki M., Miura S. Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan. Psychiatry Clin. Neurosci. 55:2001;353-363.
21. 1A receptor. Eur. J. Pharmacol. 441:2002;137-140.
22. Kasper S., Tauscher J., Kufferle B., Barnas C., Pezawas L., Quiner S. Dopamine- and serotonin-receptors in schizophrenia: results of imaging studies and implications for pharmacotherapy in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 249(Suppl. 4):1999;83-89.
23. Kikuchi T., Tottori K., Uwahodo Y., Hirose T., Miwa T., Oshiro Y., Morita S. 7-{4-[(2,3-Dichlorophenyl)-1-Piperazinyl]Butyoxy}-3,4-Dihydro-2 (1H)-Quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic and postsynaptic D2 receptor antagonist activity. J. Pharmacol. Exp. Ther. 274:1995;329.
24. Kujawa M., Saha A.R., Ingenito G.G., Ali M.W., Luo X., Archibald D.G., Carson W.H. Aripiprazole for long-term maintenance treatment of schizophrenia. Int. J. Neuropsychopharmacol. 5(Suppl. 1):2002;S186.
25. Kurzthaler I., Fleishhacker W.W. The clinical implications of weight gain in schizophrenia. J. Clin. Psychiatry. 62(Suppl. 7):2001;32-37.
26. Leucht S., Pitschel-Walz G., Abraham D., Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr. Res. 35:1999;51-68.
27. 2 receptors. Psychopharmacology. 112:1993;S40.
28. Maguire G.A. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J. Clin. Psychiatry. 63(Suppl. 4):2002;56-62.
29. Marder S.R., Davis J.M., Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J. Clin. Psychiatry. 58:1997;538-546.
30. Millan M.J. Improving the treatment of schizophrenia: focus on serotonin (5-HT)1A receptors. J. Pharmacol. Exp. Ther. 295:2000;853-861.
31. Raheja R.K., Bharwani I., Penetrante A.E. Efficacy of risperidone for behavioral disorders in the elderly: a clinical observation. J. Geriatr. Psychiatry Neurol. 8:1995;159-161.
32. Rao M.L., Möller H.J. Biochemical findings of negative symptoms in schizophrenia and their positive relevance to pharmacologic treatment. Neuropsychobiology. 30:1994;160-164.
33. Ray W.A., Meredith S., Thapa P.B., Meador K.G., Hall K., Murray K.T. Antipsychotics and the risk of sudden cardiac death. Arch. Gen. Psychiatry, Dec. 58(12):2001;1161-1167.
34. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J. Clin. Psychiatry. 60(Suppl. 10):1999;5-14.
35. Saha A.R., Carson W.H., Ali M.W., Dunbar G.C., Ingenito G. Efficacy and safety of aripiprazole and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. W. J. Biol. Psychiatry. 2(Suppl. 1):2001;305S.
36. Song F. Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials. J. Psychopharmacol. 11:1997;65-71.
37. Stahl S.M. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics: Part 1. "Goldilocks" actions at dopamine receptors. J. Clin. Psychiatry. 62:2001;824-841.
38. Stahl S.M. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics: Part 2. Illustrating their mechanism of action. J. Clin. Psychiatry. 62:2001;923-924.
39. Tollefson G., Beasley C.M. Jr., Tran P.V., Street J.S., Kreuger J.A., Tamura R.N., Graffeo K.A., Thieme M.E. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J. Psychiatry. 154:1997;457-465.
40. Wang P.S., Walker A.M., Tsuang M.T., Orav E.J., Glynn R.J., Levin R., Avorn J. Dopamine antagonists and the development of breast cancer. Arch. Gen. Psychiatry. 59:2002;1147-1154.
41. Wetterling T. Bodyweight gain with atypical antipsychotics. A comparative review. Drug Safety. 24:2001;59-73.
42. Wetterling T., Mussigbrodt H.E. Weight gain: side effect of atypical neuroleptics? J. Clin. Psychopharmacol. 19:1999;316-321.
43. Wirshing D.A., Wirshing W.C., Kysar L., Berisford M.A., Goldstein D., Pashdag J., Mintz J., Marder S.R. Novel antipsychotics: comparison of weight gain liabilities. J. Clin. Psychiatry. 60:1999;358-363.
44. Worrel J., Marken P.A., Beckman S.E., Ruehter V.L. Atypical antipsychotic agents: a critical review. Am. J. Health-Syst. Pharm. 57:2000;238-258.
45. Yeung P.P., Carson W.H., Saha A.R., McQuade R.D., Ali M.W., Stringfellow J.C., Ingenito G. Efficacy of aripiprazole, a novel antipsychotic, in schizophrenia and schizoaffective disorder: results of a placebo-controlled trial with risperidone. Eur. Neuropsychopharmacol. 11(Suppl. 3):2001;S241.